Company Overview and News

 
Is T. Rowe Price Still A 'Low Bar' Investment?

2018-09-11 seekingalpha
A year and a half ago, I looked at T. Rowe Price as a “low bar” investment.
TROW

1
Friday’s Biggest Winners and Losers in the S&P 500

2018-09-07 247wallst
September 7, 2018: The S&P 500 closed down 0.2% at 2,871.87. The DJIA closed down 0.3% at 25,918.10. Separately, the Nasdaq was down 0.3% at 7,902.54.
TROW AVGO BRCM

 
Get Ready For: Declines, Recoveries, And Growth - Blog #537

2018-08-12 seekingalpha
One of the prior major stock market declines was signaled when the O'Hare airport authorities would not let United Airlines (NYSE:UAL) sell its gate positions to reduce its debt. We may be approaching a similar signal. Media reports that after 31 years of owning the management company for Oppenheimer Funds, Mass Mutual Insurance is considering putting it up for sale at around 2% of assets under management.
TROW UAL

4
Will Zero-Fee ETFs and Mutual Funds Destroy the Profitability of Investment Managers?

2018-08-09 247wallst
When investors place money with mutual fund managers or invest in exchange traded funds and equities, they automatically assume that they will have to pay fees. These may be one-time fees, or they may be paid out each year. So what happens when investors hear that one of the nation’s top money managers is now willing to allow investors to buy two funds without any management fees at all?
BLK SCHW ETFC TROW BEN

8
5 Companies Making Giant Buybacks

2018-08-08 investorplace
Thanks to the Republican tax plan and increasing revenues, investors are seeing a bit more green in their pockets. That’s courtesy of rising buyback activity. So far, 2018 has been a record year for buybacks, with companies already authorizing $754 billion worth. However, given the continued jump to cash flows and balance sheets, analysts at Goldman Sachs estimate that we’ll actually hit the trillion-dollar mark in terms of buyback activity by the time the year ends.
AMGN V PKW TROW AAPL

83
Jane's June Dividend Increases And Income - Retirement Accounts

2018-07-19 seekingalpha - 2
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT WBA ENB OPRF JCI HSY ABBV MMM POL MO DUKH GD TRV MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL

33
5 Dividend Aristocrat ETFs for a Growing Retirement Income

2018-07-06 investorplace - 1
The average retirement lasts for 18 years in the United States. Hence, when investing for retirement, investors need to consider how inflation will affect their income. Allocations into retirement stocks should be set with income in mind.
FOJCF O CSL OPRF KMB KCDMY FOJCY T KMB.WI TROW ABBV CFR MCD NNN ABBV

14
Vipshop Holdings: Trade War Headwinds And Margin Compression

2018-07-03 seekingalpha
The company's changing business model and lack of scale leave them more vulnerable than the competition.
JD VIPS TROW TTM

75
5 ROE Stocks to Buy as Proposed Auto Tariffs Rattle Markets

2018-07-02 investorplace
Uncertainty gripped the equity markets on the news that the Trump administration is mulling to impose tariffs on imported cars, citing an obscure ruling to protect domestic auto manufacturers. The purported move is likely to backfire and adversely impact the operations of several auto manufacturing firms, leading to job loss and decline in production.
AMCX BSX TROW GM CE

127
7 Debt-Free Companies Doing Big Stock Buybacks | InvestorPlace

2018-06-21 investorplace
Securities and Exchange Commissioner Robert Jackson Jr. gave a speech June 11 in Washington D.C. In it, he outlined the reasons why the securities watchdog is overhauling the rules for stock buybacks; the first time in 15 years.
RHI ALGN HGRL AMZN TROW LULU MNST NYTAB FIVE

358
Jane's May Dividend Income Tracker - Retirement Accounts

2018-06-19 seekingalpha
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG DUKH GD TRV MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL

206
Venture Capital Deals Of The Week: Ant Financial Gets $14B Ahead Of IPO

2018-06-09 seekingalpha
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings.
IBM JD WDC APPN CG CRM HPE GS BABA DVMT ATHM TROW MSFT NTAP

130
ESG Funds: Impact And Alpha

2018-06-06 seekingalpha - 1
This article originally appeared in the June issue of Wealth Management magazine and online at Brad Zigler.
SNSR AND TXN LIT KRMA BFIT GXG SIL ADP GXF ESG CHII ACTX CHIE GOEX FINX CHIX 3772 MSCI SRET BOTZ CATH ESGU GURX GURI DSI ALUM MILN CJHIQ URA LNGR ADPVV TROW COPX ABBV QQQC GURU

98
5 Dividend Aristocrat ETFs for a Growing Retirement Income | InvestorPlace

2018-05-30 investorplace
The average retirement lasts for 18 years in the United States. Hence, when investing for retirement, investors need to consider how inflation will affect their income. Allocations into retirement stocks should be set with income in mind.
FOJCF O CSL OPRF KMB KCDMY FOJCY KMB.WI TROW ABBV CFR MCD NNN ABBV

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to TROW / Price (T.) Rowe Group, Inc. on message board site Silicon Investor.

MWBX Metrowest bank(Framingham,Ma.) MWBX Metrowest bank(Framingham,Ma.) MWBX Metrowest bank(Framingham,Ma.) T. Rowe Price (TROW) T. Rowe Price (TROW) T. Rowe Price (TROW)
Metrowerks (MTWK) Metrowerks (MTWK) Metrowerks (MTWK) Metrowerks (MTWKF) - low volume, low visibility Metrowerks (MTWKF) - low volume, low visibility Metrowerks (MTWKF) - low volume, low visibility
CUSIP: 74144T108